Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13534491 | 0.77 | PSEN1 (0.45) | HTR2AHTR2CKCNH2DRD2PSEN1 | |
| SCHEMBL1365544 | 0.75 | PSEN1 (0.40) | HTR2AHTR2CKCNH2DRD2PSEN1 | |
| SCHEMBL1364594 | 0.71 | ALDH1A1 (0.37) | HTR2AHTR2CKCNH2DRD2PSEN1 | |
| SCHEMBL12147220 | 0.71 | MEN1 (0.41) | HTR2AHTR2CKCNH2DRD2PSEN1 | |
| SCHEMBL14461137 | 0.71 | MEN1 (0.41) | HTR2AHTR2CKCNH2DRD2PSEN1 | |
| SCHEMBL1363575 | 0.70 | DRD2 (0.36) | HTR2AHTR2CKCNH2DRD2PSEN1 | |
| SCHEMBL8231928 | 0.70 | CYP3A4 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1363237 | 0.70 | DRD2 (0.38) | HTR2AHTR2CKCNH2DRD2PSEN1 | |
| SCHEMBL1362802 | 0.70 | CYP3A4 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1362911 | 0.70 | MAPT (0.42) | HTR2AHTR2CKCNH2DRD2PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| US-8569521-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-1976843-B1 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| EP-1976843-B1 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-09-04 | — | — | EP | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2012-10-18 | — | — | US | disclosed |
| US-8067621-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067621-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067621-B2 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | SCHERING CORPORATION (US) | 2011-11-29 | — | — | US | disclosed |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | MERCK SHARP & DOHME LLC | 2007-08-23 | — | — | US | disclosed |
| WO-2007084595-A2 | CARBOCYCLIC AND HETEROCYCLIC ARYLSULFONES AS GAMMA SECRETASE INHIBITORS | SCHERING CORPORATION (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120264736-A1 | BENZENESULFONYL-CHROMANE, THIOCHROMANE, TETRAHYDRONAPHTHALENE AND RELATED GAMMA SECRETASE INHIBITORS | BACE1, PSEN1, BACE2 | HTR2A 2088/4885HTR2C 2081/4885KCNH2 2063/4885 |
| US-20070197581-A1 | Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors | BACE1, BACE2, PSEN1 | HTR2A 1869/4885HTR2C 1890/4885KCNH2 2185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.